BRK-B vs NMR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
Nomura Holdings presents a stark contrast between attractive valuation and poor operational health, highlighted by a weak Piotroski F-Score of 2/9. While the stock trades significantly below its Graham Number ($11.50) and Intrinsic Value ($10.31), the fundamental health metrics are concerning. Strong revenue growth and a healthy dividend yield are offset by extreme leverage (Debt/Equity of 9.17) and a consistent track record of missing earnings estimates. The current price of $8.06 suggests a value play, but the lack of operational momentum warrants a neutral stance.
Compare Another Pair
Related Comparisons
BRK-B vs NMR: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Nomura Holdings, Inc. (NMR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.